SCHEMBL769305

SCHEMBL769305

CCCCc1ccc(CNc2ccc3c(c2)ncn3-c2ccc(OC)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.64
KDM4E B2RXH2 9/20 0.64
NPC1 O15118 6/20 0.64
RAB9A P51151 6/20 0.64
ALDH1A1 P00352 9/20 0.63
HPGD P15428 8/20 0.63
TDP1 Q9NUW8 3/20 0.63
L3MBTL1 Q9Y468 3/20 0.63
GAA P10253 3/20 0.63
SMN1; SMN2 Q16637 7/20 0.62
LMNA P02545 3/20 0.62
ALOX15 P16050 2/20 0.62
TSHR P16473 1/20 0.62
KIT P10721 2/20 0.58
FLT3 P36888 2/20 0.58
HSD17B10 Q99714 2/20 0.54
TP53 P04637 2/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
HTT P42858 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769657 0.96 MAPT (0.61) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL769808 0.94 MAPT (0.66) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL769578 0.93 MAPT (0.65) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL770038 0.92 MAPT (0.72) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL769958 0.90 MAPT (0.61) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL769865 0.89 MAPT (0.69) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL769148 0.89 MAPT (0.70) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL769809 0.89 MAPT (0.65) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL769848 0.89 MAPT (0.69) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL769828 0.87 KDM4E (0.67) MAPTKDM4ENPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US claimed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection ZC3HAV1, GZMB, GTF3C3 MAPT 2844/4885KDM4E 1661/4885NPC1 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.